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Key Clinical Message
The treatment with fondaparinux is the effective and safe anticoagulant therapy
in liver transplant patient on immunosuppressive therapy with arterial throm-
bosis, and it seems able to reduce liver fibrosis. Although this treatment is not
generalizable, further prospective large studies need to confirm this case report.
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Introduction
The treatment of deep vein thrombosis (DVT) is well
established, and evidence-based guidelines [1] are regu-
larly updated, whereas the management of vein/artery
thrombosis in patients with liver fibrosis and/or cirrhosis
has not yet been validated.
The incidence of thrombosis among patients undergo-
ing orthotopic liver transplantation (OLT) is approxi-
mately 9%; the majority of events tend to occur within
the first 3 months after the transplant [2]. A recent study
of liver transplant patients reported a greater incidence of
hepatic artery and portal vein thrombosis in patients trea-
ted with a reduced dose of immunosuppressive therapy
[3]. The hepatic artery thrombosis was observed in 4.6%
of 1000 primary liver transplants, and it was one of
frequent factors for retransplants [4].
Anticoagulation therapy (AT) with low-molecular
weight heparin (LMWH) followed by the administration
of a vitamin K antagonist has been reported to be a use-
ful treatment in the management of patients waiting for
liver transplantation [5]. LMWH appears to be safe and
effective in achieving recanalization of the portal vein in
patients with cirrhosis [6]. A disadvantage of LMWH in
patients with cirrhosis is that the drug efficacy depends
on antithrombin. Indeed, antithrombin levels can be sig-
nificantly reduced in cirrhotic patients. Recently, warfarin
anticoagulation was proposed as a treatment for liver
fibrosis in patients undergoing liver transplantation for
hepatitis C [7].
Since 2003, physicians have been using fondaparinux.
Fondaparinux is a synthetic indirect factor Xa inhibitor,
which mediates its effects indirectly through antithrombin
but, unlike heparin, is selective for factor Xa [8].
Case Report
A 53-year-old woman presented with left renal artery
thrombosis in July 2012. The patient, who was seronega-
tive for HCV, HBV, and HIV, underwent liver transplan-
tation for Caroli’s syndrome in 2005 and started on
immunosuppressive therapy with tacrolimus. Caroli’s
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syndrome is a combination of Caroli’s disease (bouts of
cholangitis, hepatolithiasis, and gallbladder stones) with
congenital hepatic fibrosis (portal hypertension). Clinical
progression and presentation of Caroli’s syndrome are
highly variable, and symptoms may appear early or late
during life [9].
Ultrasound (US)–Doppler, and angio-magnetic reso-
nance imaging (MRI) were performed in October 2006
and showed no sign of a hepatic disorder. Liver function
was preserved, and transaminases were within the normal
range. These findings were confirmed by subsequent US–
Doppler and blood tests, which were regularly performed
during the five-year follow-up period (Table 1). In March
2009, after 39 months from the liver transplant, the
patient exhibited hypertension related to left renal artery
stenosis. The treatment for the stenosis consisted of stent-
ing and drug therapy with dipyridamole (75 mg/day). At
this time, the immunosuppressive therapy was adjusted
according to the patient’s renal function.
In July 2012, after 78 months from the liver transplant,
the US–Doppler imaging suggested that the liver had
undergone fibrosis. Stiffness was evaluated by Acoustic
Radiation Force Impulse (ARFI) and was equal to
16.85 m/sec. The mean value of ARFI measurements in
normal individuals was 1.15  0.21 m/sec [10]. In addi-
tion, the imaging technique showed a thrombotic event
in the left renal artery. The patient’s clinical characteris-
tics at the time of this thrombotic event are shown in
Table 2.
The patient had no family history of thrombosis. She
arrived at the Thrombosis Centre of Hematology and
underwent blood tests, which ruled out the presence of
inherited conditions such as protein C, protein S, and
antithrombin deficiencies or G20210A, G1691A, and
JAK2 mutations. The presence of acquired prothrombotic
systemic factors was also excluded.
Although the patient did not have any visible varicose
esophageal veins and the creatinine clearance was 46 mL/
min, physicians decided to treat the artery thrombosis
with 2.5 mg/daily of fondaparinux for 12 months. This
treatment is considered off-label, although a large study
showed the efficacy and safety of treatment with fonda-
parinux 2.5 mg/daily in patients with acute coronary syn-
dromes (ACS) which is considered an arterial thrombosis
[11].
No pharmacological interference between fondaparinux
and the drugs taken by the patient, which included tacro-
limus, ursodeoxycholic acid, and a beta-blocker, were
noted.
In July 2013, after 12 months from the start of the
therapy, the patient underwent abdominal US–Doppler,
kidney scintigraphy, and blood tests (Table 2). Imaging
techniques and blood tests showed both recanalization of
the left renal artery and an increase in the portal vein
speed, which was associated with a reduction in liver
fibrosis. The authors decided to stop the AT and moni-
tored the patient every 4 months with US–Doppler and
biochemical parameters.
In January 2015, the patient was on immunosuppres-
sive therapy with a low dose of tacrolimus in order to
obtain a plasmatic concentration of 2.6 ng/mL. At this
time, the patient developed two new thrombotic events:
one involved the left renal artery, and the other involved
the common iliac artery. These two events were diagnosed
by abdominal X-ray computed tomography. At the same
time, US–Doppler imaging showed that the liver fibrosis
was equal to 1.7 m/sec. The extent of fibrosis was evalu-
ated using ARFI.
The patient underwent further therapy with fonda-
parinux at 2.5 mg/daily, and after 5 months, both throm-
boses were completely resolved the second time. In
addition, US–Doppler imaging showed a reduction in
Table 1. Clinical parameters of the patient during the five years after
liver transplantation.
Parameters 2006 2008 2010
Albumin gr/dL 3.6 3.7 4.5
GPT (U/L) 21 20 29
GOT (U/L) 24 21 33
GGT (U/L) 18 15 19
Creatinine (mg/dL) 1.1 1.0 1.0
Tacrolimus (FK506) ng/mL 7.0 6.1 3.6
Fibrosis (Metavir) F0 F0 F0-1
Portal vein* (mm) 10.4 12.4 11.0
Portal flow† (cm/sec) 19.5 13.6 12.6
*Vessel diameter.
†Blood speed.
Table 2. Clinical parameters before and after anticoagulant therapy
with fondaparinux.
July 2012 (Before
fondaparinux)
July 2013 (After
fondaparinux)
Age (years) 53 54
Weight (kg) 68 65
Creatinine clearance (mL/min) 46 64
Factor VIII (%) 178 130
Homocysteinemia (lmol/mL) 17 13
Liver stiffness (ARFI) 16.85 5.71
Fibrosis (Metavir) F4 F0-1
Portal vein* (mm) 8.2 13.4
Portal flow† (cm/sec) 14.8 22.7
Reference range: Factor VIII = 65–130%. Homocysteinemia =
8–15 lmol/mL.
*Diameter.
†Speed.
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liver fibrosis to 1.4 m/sec; this value was lower than that
observed after the first treatment with fondaparinux.
Currently, the patient continues to be on anticoagulant
therapy with fondaparinux. The aim is to reduce the
thrombotic risk, as the tacrolimus plasmatic concentra-
tion (2.6 ng/mL) was also reduced according to clinical
criteria.
Discussion
The management of vein/artery thrombosis in patients
with liver fibrosis and/or cirrhosis is not evaluated. A
study reported the safety and effectiveness of LMWH in
achieving recanalization of the portal vein in patients with
cirrhosis [6]. One disadvantage when using LMWH in
patients with cirrhosis may be the unpredictable efficacy
of this drug, given that LMWH requires antithrombin to
exert its anticoagulation function.
A retrospective study reported an incidence of 27 DVTs
after liver transplantation (LT) among 304 patients who
were followed at a single institution from 2005 to 2012
[2]. Among patients with and without DVT, there was no
significant difference in the following preoperative risk
factors: age, sex, platelet count, INR value, and the pres-
ence of infections and/or cancer. The risk of DVT was
related to both the difference in mobility and the periop-
erative use of factor VII. The risk of developing a DVT
after liver transplantation was 9% even with mechanical
DVT prophylaxis [2]; the risk is higher in the first
3 months after a liver transplant.
Recently, warfarin anticoagulation was proposed for
patients with liver fibrosis undergoing liver transplanta-
tion for hepatitis C [7].
Francoz et al. [5] assessed the usefulness of anticoagu-
lation therapy with LMWH followed by administration of
a vitamin K antagonist in patients waiting for liver trans-
plantation.
The arterial thrombosis observed in our patient could
be considered as late thrombosis, which was not related
to the liver transplantation but due to concomitant
events, including the change in immunosuppressive ther-
apy and the stent insertion.
Battinelli et al. [12] showed that platelets, when
exposed to heparin, tended to release a significantly smal-
ler amount of vascular endothelial growth factor in
response to adenosine 50-diphosphate. The microparticle
released from these platelets contained less proangiogenic
proteins. In addition, these platelets exhibited decreased
angiogenic potential. Fondaparinux showed a similar
effect on the platelet angiogenic potential. Moreover, fon-
daparinux seems to inhibit the generation of thrombin by
activated monocytes and monocyte-derived microparticles
(MMPs) via tissue factor; this inhibition is known to be
dose-dependent. Monocytes and MMPs play a major role
in ACS. Indeed, the efficacy of fondaparinux at a daily
dose of 2.5 mg in ACS patients appears to be related to
its inhibitory effect on MMPs [13].
In addition, Abe et al. [14] reported that LMWH,
such as dalteparin sodium, up-regulates serum hepatic
growth factor to prevent proliferation of hepatic stellate
cells (HSC) and down-regulates the transforming growth
factor levels in rats exposed to carbon tetrachloride for
an extended period of time. Therefore, our hypothesis is
that fondaparinux could exert antifibrogenic effects by
direct inhibition of HSC proliferation. Indeed, these cells
play a key role in liver fibrinogenesis which could be
inhibited by the reduced amount of thrombin secondary
to the administration of both LMWHs and fondaparinux
[15].
As is the case for any LMWH, fondaparinux is metabo-
lized by the kidney; therefore, caution is required when
administering fondaparinux to patients with impaired
kidney function, which is defined by a creatinine clear-
ance below 30 mL/min. Caution is needed because the
bleeding risk is increased in these patients.
This report suggests that fondaparinux appears to be
effective and safe in the anticoagulant treatment of
patients with thrombosis and liver fibrosis. Given that the
treatment with fondaparinux is uncommon for liver
transplant patients, other unknown factors may have
played a role in the resolution of arterial thrombosis and
liver fibrosis of our patient. Although this treatment is
not generalizable, further prospective studies on a large
cohort of patients are needed to confirm this case report.
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